Symbols

RMD

ResMed

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 4

Sell signal 1

Dividend Princes

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RMD

Resmed Inc.

A leading developer and manufacturer of medical devices for sleep-disordered breathing and respiratory care

Industry

Healthcare Equipment and Supplies

Established Date

Invalid Date

Listing Date

09/30/1999

Exchange

New York Stock Exchange

Full-time Employees

10,140

Fiscal Year Ends

06-30

Website

www.resmed.com

Security Type

Common stock

Office address

9001 Spectrum Center Blvd., San Diego, CA 92123, United States of America

Business

Medical device manufacturing

Introduction

ResMed Inc., a Delaware corporation, was founded in March 1994. The company is a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory diseases, including sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular diseases and other chronic diseases. The company's products and solutions are designed to improve patients' quality of life, reduce the impact of chronic diseases, and reduce health care costs as the global health care system continues to drive the transfer of care from hospitals to homes and low-cost environments. The company's cloud-based digital software health applications, as well as devices, are designed to provide connected care to improve patient outcomes and increase customer efficiency.

Company Financials

EPS

RMD has released its 2025 Q3 earnings. EPS was reported at 2.37, versus the expected 2.36, beating expectations. The chart below visualizes how RMD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RMD has released its 2025 Q3 earnings report, with revenue of 1.29B, reflecting a YoY change of 7.92%, and net profit of 365.04M, showing a YoY change of 21.48%. The Sankey diagram below clearly presents RMD's revenue sources and cost distribution.